Sònia Pernas

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Antonio Llombart‐Cussac, Javier Cortés, Laia Paré et al. · The Lancet Oncology · 2017 · 329 citations

Breast Oncology, Medicine, Pathology +8

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Sara M. Tolaney, Hao Guo, Sònia Pernas et al. · Journal of Clinical Oncology · 2019 · 276 citations · Full text

Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

Romualdo Barroso‐Sousa, Tanya E. Keenan, Sònia Pernas et al. · Clinical Cancer Research · 2020 · 174 citations · Full text

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

Sònia Pernas, Miguel Martín, Peter A. Kaufman et al. · The Lancet Oncology · 2018 · 133 citations

Breast Oncology, Oncology, Medicine +8